Memorial Sloan Kettering Cancer Center: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 14 Lymphoma, Large B-Cell, Diffuse studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 6Phase 2 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingNCT06765317Phase 2
• A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell LymphomaRecruitingNCT06736613Phase 2
• Study of a Communication Training Intervention for Large B-Cell Lymphoma ProvidersRecruitingNCT05940272Not applicable
• Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaRecruitingNCT04512716Early Phase 1
• Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaTerminatedNCT02282358Phase 1/2Results posted
• Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell LymphomaCompletedNCT00712582Phase 2Results posted
• Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT00667615Phase 1/2Results posted
• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
• Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
• A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
• Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT02570542Phase 2
• Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase TherapyActive, not recruitingNCT01829958Not applicable
• Communication Skills Intervention to Promote Transition Into SurvivorshipActive, not recruitingNCT01483664
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1